A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer

Autor: Rustin, G., Vergote, I., Micha, J.P., Duska, L.R., Reed, N., Bendell, J., Spitz, D., Dark, G., Hoch, U., Tagliaferri, M., Hannah, A.L., Garcia, A.A.

Publikováno v: In Gynecologic Oncology November 2017 147(2):276-282

An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor

Autor: Gore, M, Hackshaw, A, Brady, WE, Penson, RT, Zaino, R, McCluggage, WG, Ganesan, R, Wilkinson, N, Perren, T, Montes, A, Summers, J, Lord, R, Dark, G, Rustin, G, Mackean, M, Reed, N, Kehoe, S, Frumovitz, M, Christensen, H, Feeney, A, Ledermann, J, Gershenson, DM

Publikováno v: Gynecologic Oncology

Objectives We evaluated four different treatment regimens for advanced-stage mucinous epithelial ovarian cancer. Methods We conducted a multicenter randomized factorial trial (UK and US). Patients were diagnosed with primary mEOC: FIGO stage II–IV

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::46da48c9ce802143609b5064b749aa11
http://europepmc.org/articles/PMC6559214

Quality of life of weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study

Autor: Blagden, S, Cook, A, Poole, C, Howells, L, McNeish, I, Dean, A, Galardo, D, Kim, J, O'Donnell, D, Hook, J, James, E, Perren, T, Lord, R, Dark, G, Earl, H, Hall, M, Kaplan, R, Ledermann, J, Clamp, A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1064::b416d9f873edef5d3effafa0e55a6ade
https://ora.ox.ac.uk/objects/uuid:0d8179f8-b478-405a-a52c-97c4b86c92d5

Differentiation and Definition of Vascular-Targeted Therapies

Autor: Siemann, D. W., Bibby, M. C., Dark, G. G., Dicker, A. P., Eskens, F. A. L. M., Michael Horsman, Marmé, D., Lorusso, P. M.

Publikováno v: Scopus-Elsevier
Siemann, D W, Bibby, M C, Dark, G G, Dicker, A P, Eskens, F A L M, Horsman, M R, Marmé, D & LoRusso, P M 2005, ' Differentiation and definition of vascular-targeted therapies ', Clinical Cancer Research, vol. 11, no. 2 Pt 1, pp. 416-420 . < http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15701823&query_hl=53&itool=pubmed_docsum >
Clinical Cancer Research, 11, 416-420. American Association for Cancer Research Inc.

The therapeutic potential of targeting the tumor vascular supply is now widely recognized. Intense research and development activity has resulted in a variety of investigational agents, a number of which are currently in clinical development. As thes

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fef411d0252696c3e487e92ae9bd8475
https://doi.org/10.1158/1078-0432.416.11.2

943PD - Response to neoadjuvant chemotherapy in ICON8: A GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment

Autor: Clamp, A.R., McNeish, I.A., Dean, A., Gallardo-Rincon, D., Kim, J.-W., O’Donnell, D.M., Hook, J., Blagden, S., Brenton, J.D., Naik, R., Perren, T.J., Sundar, S., Cook, A.D., James, E.C., Gabra, H., Lord, R., Hall, M., Dark, G., Kaplan, R.S., Ledermann, J.A.

Publikováno v: In Annals of Oncology October 2018 29 Supplement 8